PATENT CLAIM ANALYSIS

Application Number: 15751542
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "391000"]

Abstract:
This disclosure provides a dosage regimen for co-administration of enzalutamide and a strong CYP3A4 inducer in the treatment of cancer.

Claim (Index 2):
The method of  claim 1 , wherein the cancer is selected from the group consisting of prostate cancer, breast cancer, and ovarian cancer.

Metadata:
- Claim Count in Document: 13.0
- Percentile: 88.0
- Lexical Diversity: 1.10526
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14882662', '11928908', '14511420', '10933479', '11451496']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7600235669338693
- 35 USC 102 Novelty (BERT): 0.495486990218198
- Combined Prediction Score: 0.7335699092623021
- Mean Citation Score: 136.960216
- Max Citation Score: 144.48193
- Similarity Product: 83.6819487754518

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test